Morgan Stanley analyst David Lewis maintained a Buy rating on Haemonetics Corp (NYSE: HAE) today and set a price target of $120. The company’s shares opened today at $105.81, close to its 52-week high of $108.37.
According to TipRanks.com, Lewis is a 4-star analyst with an average return of 14.3% and a 73.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Intuitive Surgical, and Nevro.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics Corp with a $105 average price target, which is a -0.8% downside from current levels. In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
Haemonetics Corp’s market cap is currently $5.52B and has a P/E ratio of 122.69. The company has a Price to Book ratio of 7.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.
